CN108289935A - 纤溶酶原缺乏症的纤溶酶原替代疗法 - Google Patents

纤溶酶原缺乏症的纤溶酶原替代疗法 Download PDF

Info

Publication number
CN108289935A
CN108289935A CN201680067482.XA CN201680067482A CN108289935A CN 108289935 A CN108289935 A CN 108289935A CN 201680067482 A CN201680067482 A CN 201680067482A CN 108289935 A CN108289935 A CN 108289935A
Authority
CN
China
Prior art keywords
plasminogen
subject
activity
endothelial tissue
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680067482.XA
Other languages
English (en)
Chinese (zh)
Inventor
马丁·罗比塔耶
K·蒂博多
P·劳伦
S·普拉姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Plo Mitic Biological Therapeutics Ltd
Original Assignee
Plo Mitic Biological Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plo Mitic Biological Therapeutics Ltd filed Critical Plo Mitic Biological Therapeutics Ltd
Publication of CN108289935A publication Critical patent/CN108289935A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680067482.XA 2015-11-03 2016-11-03 纤溶酶原缺乏症的纤溶酶原替代疗法 Pending CN108289935A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250235P 2015-11-03 2015-11-03
US62/250235 2015-11-03
PCT/IB2016/001599 WO2017077380A1 (en) 2015-11-03 2016-11-03 Plasminogen replacement therapy for plasminogen-deficiency

Publications (1)

Publication Number Publication Date
CN108289935A true CN108289935A (zh) 2018-07-17

Family

ID=58661917

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680067482.XA Pending CN108289935A (zh) 2015-11-03 2016-11-03 纤溶酶原缺乏症的纤溶酶原替代疗法

Country Status (16)

Country Link
US (1) US11291711B2 (enExample)
EP (1) EP3370760B1 (enExample)
JP (1) JP6878423B2 (enExample)
KR (1) KR102821400B1 (enExample)
CN (1) CN108289935A (enExample)
AU (1) AU2016347863B2 (enExample)
BR (1) BR112018008965A8 (enExample)
CA (1) CA3002915C (enExample)
FI (1) FI3370760T3 (enExample)
IL (1) IL258913B (enExample)
MX (1) MX2018005588A (enExample)
MY (1) MY199581A (enExample)
RU (1) RU2736831C2 (enExample)
TW (1) TWI801331B (enExample)
WO (1) WO2017077380A1 (enExample)
ZA (1) ZA201802820B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114354929A (zh) * 2022-01-07 2022-04-15 南京鼓楼医院 一种用于监测人体纤溶状态的试剂盒及应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201722464A (zh) * 2015-11-10 2017-07-01 波麥堤克生化科學有限公司 用於傷口癒合之纖維蛋白溶酶原給藥方案
DK3395354T3 (da) 2015-12-18 2024-06-03 Talengen Int Ltd Plasminogen til anvendelse i behandling af diabetisk nefropati
EP3395353B1 (en) 2015-12-18 2024-03-06 Talengen International Limited Plasminogen for use in treating or preventing diabetes mellitus nerve injury
TWI653982B (zh) * 2015-12-18 2019-03-21 大陸商深圳瑞健生命科學研究院有限公司 Method for preventing or treating acute and chronic thrombosis
ES2961967T3 (es) 2015-12-18 2024-03-14 Talengen Int Ltd Plasminógeno para su uso en el tratamiento de la angiocardiopatía diabética
WO2017161354A1 (en) * 2016-03-17 2017-09-21 Vanderbilt University Enhancing plasmin activity to prevent soft tissue calcification
CN110167583A (zh) * 2016-12-15 2019-08-23 泰伦基国际有限公司 一种治疗冠状动脉粥样硬化及其并发症的方法
JP7175270B2 (ja) 2016-12-15 2022-11-18 タレンゲン インターナショナル リミテッド グルカゴン、インスリンを正常なバランスに戻らせる方法
TW201822790A (zh) 2016-12-15 2018-07-01 大陸商深圳瑞健生命科學研究院有限公司 一種預防和治療皮膚纖維化的方法
CN110114081A (zh) 2016-12-15 2019-08-09 泰伦基国际有限公司 一种改善心脏病变的方法
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
CN109125715A (zh) * 2017-06-19 2019-01-04 深圳瑞健生命科学研究院有限公司 一种调控glp-1/glp-1r的方法和药物
DK3643321T3 (da) * 2017-06-19 2025-08-18 Talengen Int Ltd Plasminogen til anvendelse i behandling af parkinsons og alzheimers sygdom
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CN113597313A (zh) * 2019-01-24 2021-11-02 先觉药业咨询公司 用于治疗和预防微血栓形成的纤溶酶原
EP3812772B1 (en) * 2019-10-24 2025-02-19 Hôpitaux Universitaires de Strasbourg (HUS) Method for diagnosing fibrinolytic insufficiency related to neutrophil extracellular traps
US12497607B2 (en) * 2020-04-23 2025-12-16 Previpharma Consulting Gmbh Plasminogen for use in treating and preventing lung dysfunction
WO2025049724A1 (en) * 2023-08-29 2025-03-06 Board Of Regents Of The University Of Nebraska Compositions and methods for treating pleural space infections and hemothorax

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637299A (en) * 1992-07-01 1997-06-10 Beth Israel Hospital Enhancement of thrombolytic therapy with deglycosylated forms of plasminogen
CN1585649A (zh) * 2001-09-06 2005-02-23 奥姆尼奥公司 改善伤口愈合的方法
WO2006120423A1 (en) * 2005-05-09 2006-11-16 Prometic Biosciences Ltd. Affinity adsorbents for plasminogen
JP2010502600A (ja) * 2006-08-28 2010-01-28 オムニオ・ヒーラー・アクチボラゲット 感染症に対する候補薬

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2254316B1 (enExample) * 1973-12-18 1977-04-22 Choay Sa
JP2764264B2 (ja) * 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
AT402367B (de) * 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
EP0682700A4 (en) * 1993-02-05 1997-05-28 Vascular Lab USE OF UROKINASE-LIKE PLASMINOGEN ACTIVATORS IN THE INTERIOR OF PLATES FOR THE LONG-TERM INHIBITION OF THROMBOSE.
US20030224516A1 (en) * 2002-06-03 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of prox-1 expression
US20050271636A1 (en) * 2002-08-09 2005-12-08 St. Jude Children's Research Hospital, Inc. Diagnostic and therapeutic uses for prox 1
WO2008027000A2 (en) * 2006-08-28 2008-03-06 Omnio Healer Ab Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
WO2011004011A1 (en) * 2009-07-10 2011-01-13 Thrombogenics Nv Variants of plasminogen and plasmin
JP6343147B2 (ja) * 2010-08-30 2018-06-13 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 狭窄病変および血栓溶解療法のための剪断による制御放出
PT3233111T (pt) 2014-12-19 2024-10-10 Kedrion Biopharma Inc Composição farmacêutica que compreende éniplasminogénio e seus usos
CN108463240A (zh) * 2015-12-18 2018-08-28 泰伦基国际有限公司 一种预防或治疗糖尿病性视网膜病变的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637299A (en) * 1992-07-01 1997-06-10 Beth Israel Hospital Enhancement of thrombolytic therapy with deglycosylated forms of plasminogen
CN1585649A (zh) * 2001-09-06 2005-02-23 奥姆尼奥公司 改善伤口愈合的方法
WO2006120423A1 (en) * 2005-05-09 2006-11-16 Prometic Biosciences Ltd. Affinity adsorbents for plasminogen
JP2010502600A (ja) * 2006-08-28 2010-01-28 オムニオ・ヒーラー・アクチボラゲット 感染症に対する候補薬

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PATRICK WATTS等: "Effective Treatment of Ligneous Conjunctivitis With Topical Plasminogen", 《AMERICAN JOURNAL OF OPHTHALMOLOGY》 *
徐晓利等: "《医学生物化学》", 31 October 1998, 人民卫生出版社 *
汤新之等: "《临床生物化学》", 31 May 1999, 天津科学技术出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114354929A (zh) * 2022-01-07 2022-04-15 南京鼓楼医院 一种用于监测人体纤溶状态的试剂盒及应用

Also Published As

Publication number Publication date
MX2018005588A (es) 2018-11-09
RU2736831C2 (ru) 2020-11-20
FI3370760T3 (fi) 2025-12-05
CA3002915A1 (en) 2017-05-11
EP3370760B1 (en) 2025-10-01
AU2016347863B2 (en) 2023-11-09
KR102821400B1 (ko) 2025-06-18
WO2017077380A1 (en) 2017-05-11
AU2016347863A1 (en) 2018-06-07
JP2018533589A (ja) 2018-11-15
NZ742657A (en) 2024-04-26
CA3002915C (en) 2024-01-16
BR112018008965A8 (pt) 2019-02-26
IL258913A (en) 2018-06-28
RU2018120182A3 (enExample) 2020-04-27
US20190231854A1 (en) 2019-08-01
JP6878423B2 (ja) 2021-05-26
BR112018008965A2 (pt) 2018-11-21
IL258913B (en) 2021-12-01
TW201722463A (zh) 2017-07-01
TWI801331B (zh) 2023-05-11
EP3370760A4 (en) 2019-06-26
EP3370760A1 (en) 2018-09-12
KR20180083348A (ko) 2018-07-20
US11291711B2 (en) 2022-04-05
ZA201802820B (en) 2019-07-31
MY199581A (en) 2023-11-07
RU2018120182A (ru) 2019-12-04

Similar Documents

Publication Publication Date Title
TWI801331B (zh) 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
Shapiro et al. Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency
EA002496B1 (ru) Способы лечения состояний гиперкоагуляции или приобретенной недостаточности белка с
US20210386777A1 (en) Gas mixtures containing low concentrations of xenon and argon provide neuroprotection without inhibiting the catalytic activity of thrombolytic agents
US20090018082A1 (en) Use of Factor VIIa or Factor VIIa Equivalents for Treating Trauma
US20220160847A1 (en) Method of preventing and/or treating a plurality of diseases
Qin et al. Progress in the treatment of acute fatty liver of pregnancy and management of perioperative anesthesia review
Roldán et al. Five prothrombotic polymorphisms and the prevalence of premature myocardial infarction
Ezer et al. Neonatal purpura fulminans due to homozygous protein C deficiency
Peus et al. Coagulation factor V gene mutation associated with activated protein C resistance leading to recurrent thrombosis, leg ulcers, and lymphedema: successful treatment with intermittent compression
JP6289511B2 (ja) 羊水塞栓の治療剤
JP2009520696A (ja) 出血性ショックおよびその続発症を治療するための製剤
WO2020166557A1 (ja) 妊娠高血圧腎症の治療方法
Thachil et al. Factor X deficiency presenting as a pseudotumor: case report
JPWO2020084853A1 (ja) 凝固異常を伴う敗血症の治療及び／又は改善のための医薬
JP2014162789A (ja) 羊水塞栓症治療剤
Choi et al. A Case of Neonatal Purpura Fulminans Due to Homozygous Protein C Deficiency
HARRIS et al. 7 Fluid, electrolyte and acid-base balance
HK40059596A (en) Drug for treating and/or improving septicemia associated with coagulation abnormality
Donato et al. Cases of Note

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180717